Isabel Anez-Bruzual

Isabel Anez-Bruzual

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
IAIsabel Anez-Bruzual
Isabel Anez-Bruzual
SCSarah Coughlin
Sarah Coughlin
DCDaniel Clay
Daniel Clay
JHJordan Heiman
Jordan Heiman
MDMichaela Dungan
Michaela Dungan
BKBryson W Katona
Bryson W Katona
Objectives: Pancreatic cancer (PC) surveillance of high-risk individuals (HRIs) downstages PC and improves survival. However, it remains less clear whether PC surveillance has a positive psychosocial impact on HRIs. Herein, we aimed to define the attitudes and beliefs of HRIs undergoing PC surveillance, and the immediate and sustained psychosocial impact of PC surveillance in HRIs. Methods: 100 HRIs undergoing PC surveillance by endoscopic ultrasound (EUS) completed three surveys addressing different components of the psychosocial impact of PC surveillance. Logistic regression analyses were performed to identify predictive factors relating to these components. Results: Most HRIs reported increased perceived benefits of PC surveillance, self-efficacy, and perceived severity of PC. HRIs reported few negative emotions prior to surveillance and frequent positive emotions after surveillance. Compared to prior to surveillance, there was a 53.5% decrease in the level of distress reported by HRIs after surveillance, which was sustained for 4–6 weeks post-surveillance. Family history of PC and lower self-reported mental health were identified as predictors for increased perceived susceptibility to PC (p < 0.01) and greater change in distress pre- to post-surveillance (p < 0.01), respectively. Conclusions: Our findings suggest that PC surveillance can lead to sustained psychosocial benefits in HRIs.

25 February 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SSSophia R. Spiegel
Sophia R. Spiegel
COCaitlin Orr
Caitlin Orr
NENicolas U. Edgar
Nicolas U. Edgar
SCSophie R. Cahill
Sophie R. Cahill
ALAnh N. Le
Anh N. Le
KMKara N Maxwell
Kara N Maxwell
INTRODUCTION: Individuals with Li-Fraumeni syndrome (LFS), a cancer predisposition syndrome caused by TP53 pathogenic germline variants (PGV), have an increased risk of colorectal cancer (CRC). However, limited data exist on colonoscopy metrics, including total neoplasia detection rates, in patients with LFS. METHODS: We conducted a retrospective cohort study of colorectal neoplasia incidence and characteristics in 663 individuals with LFS. We determined total neoplasia detection rate, adenoma detection rate (ADR), advanced ADR, serrated lesion detection rate (SDR), and CRC detection rate, stratified by age, sex, and PGV subtype, in 311 surveillance colonoscopies from 206 adults performed January 2019 to August 2024. RESULTS: CRC was reported in 4.5% of 663 adults and 0.8% of 124 pediatric patients with LFS. Among 206 adults undergoing colonoscopy, total neoplasia detection rate, ADR, SDR, advanced precancerous polyp detection rate, and CRC detection rate were 37%, 27%, 9.3%, 4.5%, and 0.64%, respectively. Detection rates were similar between loss of function and hypomorphic PGVs. Adults aged 45–75 had higher total neoplasia detection rate, ADR, advanced ADR, SDR, and CRC detection rate than those aged 25–45. Male sex was associated with increased total neoplasia detection rate (53.7% vs 30.7%, P = 0.0004), ADR (41.2% vs 22.1%, P = 0.0013), and advanced ADR (7.5% vs 1.3%, P = 0.0105). DISCUSSION: Patients with LFS have comparable ADR and higher SDR with average-risk adults despite earlier, more frequent surveillance, irrespective of TP53 PGV subtype. Our data support current recommendations for earlier and more frequent colonoscopy surveillance than average-risk guidelines, across LFS phenotypes.

1 January 2026 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
MRMaria S. Rosito
Maria S. Rosito
ACAleck E. Cervantes
Aleck E. Cervantes
CHChristine Hong
Christine Hong
JBJoseph D. Bonner
Joseph D. Bonner
BNBita Nehoray
Bita Nehoray
DBDanielle Braun
Danielle Braun
PURPOSE: Studying rare genetic conditions often requires multicenter research to gather sufficient data. However, data from multiple institutions may include relatives from the same family enrolled at different sites, increasing the likelihood of duplicate records. This issue is compounded by the use of deidentified data, which limits the direct linkage through personal identifiers. These redundancies can bias family-based genetic studies underscoring the need for robust methods for pedigree deduplication. We propose an interpretable, active learning–based approach to efficiently identify duplicate records in genetic studies, with specific application to families with TP53 mutations in the Li-Fraumeni and TP53 : Understanding and Progress (LiFT UP) study. MATERIALS AND METHODS: Our approach combines heuristic labeling with graph-based features and a machine learning model to iteratively refine duplicate detection. We first generate a partially labeled data set leveraging mutation variant diversity and family characteristics. A random forest classifier is then trained to predict duplicate pairs, with active learning guiding iterative refinement. This method is applied to real-world pedigree data from the LiFT UP study to assess its effectiveness in a multicenter setting. RESULTS: Our method labeled pedigree pairs in data from the LiFT UP study with a high degree of automation, achieving 99.95% automated processing in the deduplication workflow. By prioritizing likely duplicates for human review, it minimized manual effort while aiming for high specificity. This automated approach avoids dependence on rule-based filters, such as identifier matching, which ultimately require manual confirmation, offering a more scalable solution for improving data quality in risk estimation. CONCLUSION: Interpretable active learning provides an effective solution for pedigree deduplication. Future work will explore refinements in identifying potential duplicates and evaluate its generalizability across other genetic data sets.

2 September 2026
Verified
Other
Open access
RMRenyta Moses
Renyta Moses
AIAlexandra Indeglia
Alexandra Indeglia
ALAlison S. Levine
Alison S. Levine
RHRyan Hausler
Ryan Hausler
GKGregory Kelly
Gregory Kelly
KMKara N Maxwell
Kara N Maxwell
Table S5: Kratz criteria assigned to carriers of R181, DN/LOF, and hypomorphic variants in the patient cohort.

2 September 2026
Verified
Other
Open access
RMRenyta Moses
Renyta Moses
AIAlexandra Indeglia
Alexandra Indeglia
ALAlison S. Levine
Alison S. Levine
RHRyan Hausler
Ryan Hausler
GKGregory Kelly
Gregory Kelly
KMKara N Maxwell
Kara N Maxwell
Table S13: Ingenuity Pathway Analysis of RNAseq data after 8hr of Nutlin-3a in MCF7 p53 R181C/- vs ± cells.

2 September 2026
Verified
Other
Open access
RMRenyta Moses
Renyta Moses
AIAlexandra Indeglia
Alexandra Indeglia
ALAlison S. Levine
Alison S. Levine
RHRyan Hausler
Ryan Hausler
GKGregory Kelly
Gregory Kelly
KMKara N Maxwell
Kara N Maxwell
Table S4: History of cancer and age of onset in carriers of R181, DN/LOF, and hypomorphic variants in the patient cohort.